Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression.

@article{Spangler2012TriepitopicAF,
  title={Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression.},
  author={Jamie B Spangler and M. T. Manzari and Elizabeth K Rosalia and Tiffany F Chen and K Dane Wittrup},
  journal={Journal of molecular biology},
  year={2012},
  volume={422 4},
  pages={532-44}
}
Dysregulation of epidermal growth factor receptor (EGFR) is a hallmark of many epithelial cancers, rendering this receptor an attractive target for cancer therapy. Much effort has been focused on the development of EGFR-directed antibody-based therapeutics, culminating in the clinical approval of the drugs cetuximab and panitumumab. Unfortunately, the clinical efficacy of these drugs has been disappointingly low, and a particular challenge to targeting EGFR with antibody therapeutics has been… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
15 Extracted Citations
39 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 15 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 39 references

Similar Papers

Loading similar papers…